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In the last decade, outbreaks of nosocomial Clostridium difficile infections (CDI) occurred worldwide. A new
emerging type, PCR-ribotype 027, was the associated pathogen. Antimicrobial susceptibility profiles of this type
were extensively investigated and used to partly explain its spread. In Europe, the incidence of C. difficile
PCR-ribotype 078 recently increased in humans and piglets. Using recommendations of the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) we
studied the antimicrobial susceptibility to eight antimicrobials, mechanisms of resistance and the relation with
previously prescribed antimicrobials in human (n=49) and porcine (n=50) type 078 isolates. Human and porcine
type 078 isolates showed similar antimicrobial susceptibility patterns for the antimicrobials tested. In total, 37% of
the isolates were resistant to four or more antimicrobial agents. The majority of the human and porcine isolates
were susceptible to amoxicillin (100%), tetracycline (100%) and clindamycin (96%) and resistant to ciprofloxacin
(96%). More variation was found for resistance patterns to erythromycin (76% in human and 59% in porcine
isolates), imipenem (29% in human and 50% in porcine isolates) and moxifloxacin (16% for both human and
porcine isolates). MIC values of cefuroxim were high (MICs >256 mg/L) in 96% of the isolates. Resistance to
moxifloxacin and clindamycin was associated with a gyr(A) mutation and the presence of the erm(B) gene,
respectively. A large proportion (96%) of the erythromycin resistant isolates did not carry the erm(B) gene. The use
of ciprofloxacin (humans) and enrofloxacin (pigs) was significantly associated with isolation of moxifloxacin resistant
isolates. Increased fluoroquinolone use could have contributed to the spread of C. difficile type 078.Introduction
Clostridium difficile is a ubiquitous organism that re-
cently emerged in both humans and animals. In humans,
C. difficile is the leading cause of nosocomial diarrhea. In
the last decade incidences of C. difficile infections (CDI)
increased, which was partly explained by the emergence
of the hypervirulent C. difficile PCR-ribotype 027 [1-3].
Since 2006, the incidence of nosocomial CDI is constant
in The Netherlands, encompassing a decrease of CDI
caused by type 027 [4]. Meanwhile, C. difficile PCR-
ribotype 078 increased and it became the third most
commonly type found in human infections in The
Netherlands and Europe [4-6]. Type 078 causes severe
diarrhea in 40% of the patients and is associated with
CDI-related mortality in 4 percent after 30 days [6].* Correspondence: ejkuijper@gmail.com
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reproduction in any medium, provided the orPatients infected with type 078 are younger and the dis-
ease more frequently occurs outside healthcare facilities
[6]. Besides a high prevalence in human CDI, type 078 is
the main cause for CDI in neonatal piglets [7-9]. In the
United States, CDI is even the most commonly diag-
nosed cause of enteritis in neonatal piglets [10]. Morbid-
ity in an infected farrowing facility is on average 2/3 of
litters and 1/3 of individual piglets [11], but may be as
high as 97-100% [10]. Mortality due to C. difficile is usu-
ally low, nonetheless, outbreaks with mortality rates of
16% have been reported [12].
In humans, the use of antimicrobials, in particular
cephalosporins, clindamycin and fluoroquinolones, is a
major risk factor for CDI [13]. Resistance to newer
fluoroquinolones was used to partly explain the emer-
gence of type 027 in healthcare centers [1-3]. For type
078, especially porcine type 078, antimicrobial suscepti-
bility profiles are less extensively investigated. Therefore,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and














































































































































































































































































































Figure 1 Antimicrobial susceptibility patterns of piglet and human C. difficile for eight antimicrobial agents, the grey bars indicate the
antimicrobial susceptibility patterns of wild-type C. difficile as determined by EUCAST [14].
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and mechanisms of resistance for C. difficile type
078 isolates of human and porcine origin and to as-
sess if a specific resistance is related to prior antimicro-




Human n=49 Pig n=50 ECOFFa (mg/L) Brea
Amoxicillin 0.25 0.25 2 16
Cefuroxim ≥256 ≥256 - -
Clindamycin 2 2 ≥256 8
Erythromycin ≥256 ≥256 ≥256 8
Ciprofloxacin ≥32 ≥32 ≥32 8
Moxifloxacin 8 8 ≥64 8
Tetracycline 8 8 8 16
Imipenem ≥32 ≥32 8 16
a ECOFF: Epidemiological cut-off value - The European Committee on Antimicrobial
b CLSI: Clinical and Laboratory Standards Institute.
NA: not applicable. This is stated because no breakpoint was determined by the CLMaterials and methods
Sample selection
Between April 2009 and January 2010 we visited 25
Dutch pig breeder farms. Twenty-two farms had prob-
lems with recurrent diarrhea in neonatal piglets, threets, stratified for origin of the sample
Resistant isolates according to CLSIb (%)
kpoint (mg/L) Human n=49 Pig n=50 Difference p-value
0 (0%) 0 (0%) 1.00
NA NA NA
3 (6%) 1 (2%) 0.30
29 (59%) 38 (76%) 0.07
46 (94%) 48 (96%) 0.044
8 (16%) 8 (16%) 0.067
0 (0%) 0 (0%) 1.00
14 (29%) 25 (50%) 0.03
Susceptibility Testing (EUCAST).
SI and, therefore, the percentage of resistant isolates could not be determined.
Table 2 Mechanisms of resistance found in C. difficile type 078 isolates
Antibiotic Origin of isolate a (total number) Mechanism of resistance N. of positive isolates (%)
Tetracycline Human (6) tet(M) 6 (100%)
Porcine (8) 8 (100%)
Erythromycin Human (29) erm(B) 3 (10%)
Porcine (38) 0 (0%)
Clindamycin Human (3) erm(B) 3 (100%)
Porcine (1) 0 (0%)
Moxifloxacin Human (8) Aminoacid substitution in GyrA 8 (100%)
Porcine (7) 4 (57%)
a: All isolates with tetracycline MIC ≥8 mg/L (n=14), erythromycin MIC ≥4 mg/L (n=67) or clindamycin MIC ≥4 mg/L (n=4) were analysed for resistance
mechanisms. Seven of eight porcine isolates with moxifloxacin MIC ≥4 mg/L were tested for mutations.
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diarrheal piglets were sampled; at farms without diar-
rhea, piglets without signs of disease were sampled. At
every farm, faecal samples were taken from piglets from
at least three different litters. In total, 262 porcine faecal
samples were cultured as described previously [9]. DNA
was isolated from single C. difficile colonies using the
QIA amp DNA mini blood kit (QIAgen) according man-
ufacturer’s protocol. All isolates were confirmed as C.
difficile by an in-house developed PCR specific for C.
difficile glutamate dehydrogenase gene (GluD) and typed
as previously described by Bidet et al. [7] and Paltansing
et al. [23]. Out of 139 type 078 isolates, per farm two C.
difficile type 078 isolates were selected (random), except
for one farm where three isolates were selected and one
farm where one isolate was selected. Piglets were one to
seven days old. Forty-nine human type 078 isolates were
selected from all samples submitted to the Dutch na-
tional reference laboratory (mainly nosocomial diarrhea)
between June 2006 and May 2009. To avoid enhanced
selection of epidemic strains, only one strain per month
per hospital was included.Antimicrobial susceptibility and mechanisms of resistance
C. difficile was cultured in Brain Heart Infusion (BHI) broth
for 24 hours at 37°C in anaerobic conditions. Subsequently,
cultures were diluted to a 1.0 McFarland standard and
swabbed on Brucella blood agar plates, supplemented with
haemin 5 mg/L and vitamin K1 1 mg/L, E-test strips (AB
BioMérieux) were applied for tetracycline, amoxicillin,
erythromycin, clindamycin, moxifloxacin, imipemen, cefu-
roxim, and ciprofloxacin. Minimal inhibitory concentra-
tions (MICs) were determined after 48 hours incubation.
Antimicrobial susceptibility patterns of human and piglet
origin were compared to antimicrobial susceptibility pat-
terns of wild-type C. difficile isolates, as recently deter-
mined by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) [14]. To classify strainsas resistant or susceptible, Clinical and Laboratory Stan-
dards Institute (CLSI) breakpoints were used [15].
The mechanisms of resistance to tetracycline, erythro-
mycin, clindamycin and moxifloxacin were investigated in
more detail. Tetracycline isolates with MIC ≥8 mg/L were
tested for the presence of tet(M), int and tndX genes
according to previous publications by Spigaglia et al. [16],
[17]. The last two genes were used as markers for Tn916
and Tn5397-related elements, respectively. Erythromycin
and clindamycin isolates with a MIC ≥4 mg/L were tested
for the presence of the erm(B) gene and moxifloxacin iso-
lates with an MIC ≥4 mg/L were tested for mutations in
the gyr(A) and gyr(B) genes according to previously de-
scribed methods by Spigaglia et al. [18,19].
Clinical data collection and statistical analysis
At every farm the use of antimicrobials of the sampled pig-
lets was noted since their birth. Information on the anti-
biotic treatment of the patients in the three months prior
to the start of the diarrhea was collected at time of diagno-
sis. This was done by contacting the physician in charge
and consulting patient records. Data were processed using
SPAW statistical software for Windows, version 17.0. For
comparison of binary data, the Chi-square test was used. If
the expected cell count in the contingency table was less
than five, the Fisher’s exact test was used.
Results
C. difficile type 078 was detected at all 25 farms (with
and without diarrhoeal problems). Fifty porcine 078 iso-
lates and 49 human isolates were selected and included
in the study.
Antimicrobial susceptibility and mechanisms of resistance
Both human and porcine isolates had susceptibility pat-
terns comparable to other PCR-ribotypes in Europe (grey
bars in Figure 1). As shown in Table 1, MIC90 values were
also equal or lower than found in the EUCAST MIC dis-
tribution and similar antimicrobial susceptibility patterns
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the antimicrobials tested. The majority of isolates were
susceptible to amoxicillin (100%), tetracycline (100%) and
clindamycin (96%). Interestingly, only 16% of the isolates
were resistant to moxifloxacin. Variable resistance per-
centage was observed for erythromycin (76% in human
and 59% in porcine isolates) and imipenem (29% in hu-
man and 50% in porcine isolates). High MIC values were
observed for ciprofloxacin (94% resistant) and cefuroxim.
In total 14 human and 18 porcine isolates were resistant
to four antimicrobials, while 5 porcine isolates were resist-
ant to five antimicrobials (data not shown).
Of the 67 isolates resistant to erythromycin only four
isolates (6%) were resistant to clindamycin, whereas all
clindamycin resistant isolates were resistant to erythro-
mycin (data not shown). The 16 isolates resistant to
moxifloxacin were also resistant to ciprofloxacin (data
not shown).
Six human isolates and eight porcine isolates with MIC
values ranging from 8 to 12 mg/L and considered suscep-
tible, since the breakpoint for tetracycline is ≥16 mg/L,
contained a tet(M) gene and a Tn916-like element
(Table 2). Among the isolates resistant to erythromycin,
only three from human (MIC ≥ 256 mg/L) had an erm(B)
gene. These isolates were also high-level resistant to
clindamycin (MIC ≥ 256 mg/L). The erm(B) gene was not
found in a porcine isolate with resistance to both erythro-
mycin and clindamycin. Four of the seven porcine isolates
(57%; one porcine isolate was not tested) and all the hu-
man isolates (100%) resistant to moxifloxacin had the
amino acid substitution Thr82 to Ile in GyrA.
Human and farm specific antimicrobial use
Human antimicrobial use was known for 34 of 50 pa-
tients (68%). The most frequently used antimicrobial
classes were: penicillins (18/34; 53%), cephalosporins
(17/34; 50%) and fluoroquinolones (9/34; 26%; mainly cip-
rofloxacin). As all type 078 isolates had low MIC values
for amoxicillin and high MIC values for the cephalosporin
cefuroxim, we only investigated the concomitant use of
quinolones and the resistance to moxifloxacin. The use of
fluoroquinolones (mainly ciprofloxacin) was significantly
associated with resistance to moxifloxacin (4/5 patients
with prior fluoroquinolone use were resistant, versus 0/24
without fluoroquinolone treatment; p<0.01). The use of
fluoroquinolones was not associated with resistance to
ciprofloxacin, as virtually all isolates (94%) were resistant.
Penicillins (7/25 farms), the 3rd generation fluoroquino-
lone enrofloxacin (6/25 farms) and colistine (4/25 farms)
were commonly used in piglets in this study. At the three
farms with no history of diarrhea, no antimicrobials were
given to the sampled piglets. Similar to humans, the use of
enrofloxacin was significantly associated with resistance to
moxifloxacin, which was found in 5 of the 12 pigletstreated with enrofloxaxin, and in 3 of the 36 piglets not
treated with a fluorquinolone (p= 0.017). One farm was
excluded from this analysis because no information on the
use of antimicrobials was available for this farm.
Discussion
We tested C. difficile type 078 isolates from humans and
piglets for their minimal inhibitory concentration against
eight antimicrobial agents and the results were evaluated
using the wild type distribution data of EUCAST and the
breakpoint values recommended by CLSI. In general, the
results obtained indicate that type 078 isolates have similar
antimicrobial susceptibility profiles as other PCR-ribotypes,
though moxifloxacin resistance was found somewhat less
in the examined strains, since only 16% of them were re-
sistant to this antibiotic. Thirty seven percent of the iso-
lates were resistant to four or more antimicrobials, a
percentage comparable to those already described for other
C. difficile types [20].
A study concerning type specific risk factors for human
CDI in The Netherlands found that prior use of
fluoroquinolones (mainly ciprofloxacin) was associated
with CDI due type 078 [6]. Of type 078 isolates included is
this study, 94% was resistant to ciprofloxacin (second gen-
eration fluoroquinolone), but moxifloxacin (third gener-
ation) resistance was low, which is in concordance with
the low resistance (27%) found by Salomon et al., (2011).
During the rapid emergence of type 027 a decade ago, re-
sistance of type 027 against moxifloxacin was frequent
[21], which was also in line with the association of type
027 and fluoroquinolones in epidemiological studies.
Moxifloxacin is not among the most frequently used hu-
man fluoroquinolones and is not available for veterinary
use. It was however possible to establish an epidemio-
logical link between resistance to moxifloxacin and the ad-
ministration of fluoroquinolones in general (moxifloxacin
and others) in human patients (p<0.01) and piglets
(p=0.02). Since resistance can be linked with treatment
with fluoroquinolones, but resistance is infrequent com-
pared to other PCR-ribotypes isolated from human disease
(Figure 1), we doubt that increased fluoroquinolone use
alone explains the recent emergence of C. difficile type 078
in humans. In piglets, however, type 078 is virtually the only
PCR ribotype that causes disease, indicating that a species
border exists. The resistance against fluoroquinolones could
have contributed to emergence of Type 078 in pigs after
the introduction of type 078 in pig farms and the subse-
quent spread of type 078, as fluoroquinolone use was
present in many pig farms and no other C. difficile PCR
ribotypes were found.
In the Netherlands, there is a remarkable difference in
antimicrobial use in humans versus animals. The use of
antimicrobials in human medicine in the Netherlands is
among the lowest in the European Union, while veterinary
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most frequent used antibiotics for all types of disease in
sows and suckling piglets are tetracyclines, followed by tri-
methoprim/sulfonamides (co-trimoxazole) and penicillins
[24]. This difference in antimicrobial use was however not
reflected in different resistance profiles in our study.
The only discrepancy in human and porcine antimicro-
bial resistance profile was found for imipenem, with resist-
ance in 29% of the human isolates and in 50% of the
porcine isolates. Since imipenem is not used in porcine
medicine, a higher level of resistance to this antimicrobial
in porcine isolates compared to human isolates was unex-
pected. In the United states where imipenem is neither
used in porcine medicine 100% of piglet isolates had MIC
values of ≥16 mg/L [25]. No explanation for this higher
level of resistance can be found. Cross-resistance with
other antibiotics has not been described for imipenem in
gram-positive bacteria. Besides considerable overlap in
susceptibility profiles, human and porcine 078 strains also
had great genetic similarity when evaluated by multilocus
variable-number tandem repeat analysis (MLVA), whole-
genome analysis and pulsed-field gel electrophoresis
(PFGE) [7,26-28]. Using these methods, numerous human
and porcine type 078 isolates were indistinguishable and
were therefore suggested to have a high-level of genetic re-
latedness. Together with the increasing incidence of type
078, the association with community-associated CDI and
the presence of type 078 in more than 90% of the piglets
with colonization with C. difficile, the hypothesis arose
that human and piglet type 078 had a common origin.
The results of our study contribute to this hypothesis since
resistance patterns highly overlapped despite different
antimicrobial pressure [29]. However, as many resistance
genes are situated on transposons, antimicrobial suscepti-
bility studies cannot give definitive insight in the (possible)
common source of human and porcine CDI.
In this study, resistance to moxifloxacin was associated
with the aminoacid substitution Thr82 to Ile in GyrA, as
already observed in the majority of European C. difficile
clinical isolates resistant to fluoroquinolones [19,30,31].
Surprisingly, no tetracycline resistant isolates were found
in our study. However, MIC values between 8 and 12 mg/
L were observed in less than 20% of the isolates analysed.
It has been shown that C. difficile strains with reduced
susceptibility to tetracycline often carry a tet(M) gene and
are inducibly resistant when exposed to sub-inhibitory
concentrations of this antibiotic [32]. A recent Irish study
found that MLSB resistance in type 078 is less frequently
associated with erm(B) than other types [21]. Our results
support this observation since only a minority of the
erythromycin resistance (up to 10%) can be explained by
the presence of an erm(B) gene. Anyway, we did not ob-
serve any clindamycin resistant, erythromycin susceptible
078 isolate, as reported in the study mentioned above.What causes the resistance to erythromycin in 078 isolates
is currently unknown. Although other erm(B) negative an-
aerobes possess one of the other erm genes (frequently erm
classes A, F or Q) or overexpress an efflux pump, these
have not been determined in C. difficile type 078 [21].
The strengths of our study in comparison with other
reports on antimicrobial susceptibility data of C. difficile
type 078 are that a large number of isolates of different
origin were included and eight different antimicrobials
were tested [6,7,25,33]. Additionally, we compared the
antimicrobial susceptibility data with previous anti-
microbial treatments of patients and piglets. Limitations
of the study are the lack of more detailed data on previ-
ous antimicrobial use (preferably expressed as daily de-
fined dosages) and the fact that iinformation in piglets
was obtained by interviewing the farmer, which enables
reporting bias. Currently, attempts are underway to use
defined daily dosage (DDD) as a measure for antimicro-
bial use, applicable for both humans and animals.
Conclusion
The results of our study contribute to the hypothesis
that human and piglet type 078 have a common origin,
since similar antimicrobial susceptibility patterns were
found for the antimicrobials tested in human and porcine
type 078 isolates, despite a different antimicrobial pressure
in humans and pigs. The use of fluoroquinolones was sig-
nificantly associated with resistance to moxifloxacin in
both human and porcine isolates. It is possible that after
the introduction of C. difficile PCR-ribotype 078 in pig
farms, fluoroquinolones contributed to its rapid spread.
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